Publication:
Simulating Serial-Target Antibacterial Drug Synergies Using Flux Balance Analysis

Thumbnail Image

Open/View Files

Date

2016

Journal Title

Journal ISSN

Volume Title

Publisher

Public Library of Science
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Krueger, Andrew S., Christian Munck, Gautam Dantas, George M. Church, James Galagan, Joseph Lehár, and Morten O. A. Sommer. 2016. “Simulating Serial-Target Antibacterial Drug Synergies Using Flux Balance Analysis.” PLoS ONE 11 (1): e0147651. doi:10.1371/journal.pone.0147651. http://dx.doi.org/10.1371/journal.pone.0147651.

Research Data

Abstract

Flux balance analysis (FBA) is an increasingly useful approach for modeling the behavior of metabolic systems. However, standard FBA modeling of genetic knockouts cannot predict drug combination synergies observed between serial metabolic targets, even though such synergies give rise to some of the most widely used antibiotic treatments. Here we extend FBA modeling to simulate responses to chemical inhibitors at varying concentrations, by diverting enzymatic flux to a waste reaction. This flux diversion yields very similar qualitative predictions to prior methods for single target activity. However, we find very different predictions for combinations, where flux diversion, which mimics the kinetics of competitive metabolic inhibitors, can explain serial target synergies between metabolic enzyme inhibitors that we confirmed in Escherichia coli cultures. FBA flux diversion opens the possibility for more accurate genome-scale predictions of drug synergies, which can be used to suggest treatments for infections and other diseases.

Description

Keywords

Medicine and Health Sciences, Pharmacology, Pharmacokinetics, Drug Metabolism, Drug Interactions, Biology and Life Sciences, Biochemistry, Enzymology, Enzyme Chemistry, Enzyme Metabolism, Genetics, Heredity, Epistasis, Enzyme Inhibitors, Simulation and Modeling, Enzymes, Proteins, Drugs, Antimicrobials, Antibiotics, Microbiology, Microbial Control

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories